NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NOVAVAX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.82−0.44 (-3.91%)
Close on Oct 19, 2026
- Market cap
- $1.78B
- P/E (TTM)
- –
- Dividend yield
- –
NOVAVAX INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing, royalties, and other | $37.84M | $97.31M | $107.94M | $57.00M | $228.52M | $44.98M | $29.06M | $42.98M | $392.90M | $4.02M | $1.95M | $19.83M | 66.7% | -83.4% |
| Product sales | $18.85M | $42.20M | $39.20M | $13.44M | $10.72M | $621.68M | $59.25M | $41.53M | $22.59M | $89.84M | $267.95M | $2.23M | 33.3% | +75.8% |
| Supply sales | $18.85M | $32.64M | $19.61M | $13.77M | $12.82M | $13.65M | $9.48M | $3.32M | $2.68M | $7.51M | – | – | 33.3% | +47.1% |
| Nuvaxovid sales | $0 | $9.56M | $19.58M | -$332.00K | -$2.09M | $608.03M | $49.77M | $38.21M | $19.90M | $82.32M | – | – | 0.0% | -100.0% |
| Grants | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $37.94M | $164.92M | – | – |
| Royalties and other | – | – | – | – | – | – | – | – | – | $11.53M | $1.95M | $19.83M | – | – |
| Sales-Based Royalties | – | – | – | – | – | – | – | – | – | – | $2.50M | $6.00M | – | – |
| Milestone Payments | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| License Fees | – | – | – | – | – | – | – | $9.90M | $386.30M | $4.00M | – | – | – | – |
| License | – | – | – | – | – | – | – | – | $386.30M | – | – | – | – | – |
| Transfer of Technology | – | – | – | – | – | – | – | – | $3.50M | – | – | – | – | – |
| Transition Services | – | – | – | – | – | – | – | – | $110.20M | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $38.44M | $96.09M | $111.24M | $56.78M | $198.18M | $39.41M | $63.30M | $71.09M | $394.50M | -$6.43M | – | – | 67.8% | -80.6% |
| Rest of the world | $17.14M | $23.28M | $32.52M | $13.01M | $37.43M | $43.49M | $18.44M | $11.61M | $20.28M | $9.87M | – | – | 30.2% | -54.2% |
| Europe | $1.12M | $20.15M | $3.37M | $655.00K | $3.63M | $8.09M | $2.11M | $1.81M | $705.00K | $90.42M | – | – | 2.0% | -69.2% |
| Canada | $0 | $0 | – | $0 | $0 | $575.67M | – | $0 | $0 | $0 | – | – | 0.0% | – |
From the segment and revenue-disaggregation notes of Novavax's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.